Effectiveness study of atropine for progressive myopia in Europeans

J R Polling, R G W Kok, J W L Tideman, B Meskat, C C W Klaver, J R Polling, R G W Kok, J W L Tideman, B Meskat, C C W Klaver

Abstract

PurposeRandomized controlled trials have shown the efficacy of atropine for progressive myopia, and this treatment has become the preferred pattern for this condition in Taiwan. This study explores the effectiveness of atropine 0.5% treatment for progressive high myopia and adherence to therapy in a non-Asian country.MethodsAn effectiveness study was performed in Rotterdam, the Netherlands. Overall 77 children (mean age 10.3 years±2.3), of European (n=53), Asian (n=18), and African (n=6) descent with progressive myopia were prescribed atropine 0.5% eye drops daily. Both parents and children filled in a questionnaire regarding adverse events and adherence to therapy. A standardized eye examination including cycloplegic refraction and axial length was performed at baseline and 1, 4, and 12 months after initiation of therapy.ResultsMean spherical equivalent at baseline was -6.6D (±3.3). The majority (60/77, 78%) of children adhered to atropine treatment for 12 months; 11 of the 17 children who discontinued therapy did so within 1 month after the start of therapy. The most prominent reported adverse events were photophobia (72%), followed by reading problems (38%), and headaches (22%). The progression rate of spherical equivalent before treatment (-1.0D/year±0.7) diminished substantially during treatment (-0.1D/year±0.7) compared to those who ceased therapy (-0.5D/year±0.6; P=0.03).ConclusionsDespite the relatively high occurrence of adverse events, our study shows that atropine can be an effective and sustainable treatment for progressive high myopia in Europeans.

Figures

Figure 1
Figure 1
Mean change in SE from baseline 1 year before and during the year of treatment. Error bars present 95% CI.

References

    1. Morgan IG, Ohno-Matsui K, Saw SM. Myopia. Lancet 2012; 379(9827): 1739–1748.
    1. Pan CW, Ramamurthy D, Saw SM. Worldwide prevalence and risk factors for myopia. Ophthalmic Physiol Opt 2012; 32(1): 3–16.
    1. Sun J, Zhou J, Zhao P, Lian J, Zhu H, Zhou Y et al. High prevalence of myopia and high myopia in 5060 Chinese university students in Shanghai. Invest Ophthalmol Vis Sci 2012; 53(12): 7504–7509.
    1. Williams KM, Bertelsen G, Cumberland P, Wolfram C, Verhoeven VJ, Anastasopoulos E et al. Increasing prevalence of myopia in Europe and the impact of education. Ophthalmology 2015; 122(7): 1489–1497.
    1. Vongphanit J, Mitchell P, Wang JJ. Prevalence and progression of myopic retinopathy in an older population. Ophthalmology 2002; 109(4): 704–711.
    1. Verhoeven VJ, Wong KT, Buitendijk GH, Hofman A, Vingerling JR, Klaver CC. Visual consequences of refractive errors in the general population. Ophthalmology 2015; 122(1): 101–109.
    1. Walline JJ, Lindsley K, Vedula SS, Cotter SA, Mutti DO, Twelker JD. Interventions to slow progression of myopia in children. Cochrane Database Syst Rev 2011; (12): CD004916.
    1. Sun Y, Xu F, Zhang T, Liu M, Wang D, Chen Y et al. Orthokeratology to control myopia progression: a meta-analysis. PLoS One 2015; 10(4): e0124535.
    1. Gwiazda J. Treatment options for myopia. Optom Vis Sci 2009; 86(6): 624–628.
    1. Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL et al. Atropine for the treatment of childhood myopia. Ophthalmology 2006; 113(12): 2285–2291.
    1. Schmid KL, Wildsoet CF. Inhibitory effects of apomorphine and atropine and their combination on myopia in chicks. Optom Vis Sci 2004; 81(2): 137–147.
    1. Brodstein RS, Brodstein DE, Olson RJ, Hunt SC, Williams RR. The treatment of myopia with atropine and bifocals. A long-term prospective study. Ophthalmology 1984; 91(11): 1373–1379.
    1. Fang YT, Chou YJ, Pu C, Lin PJ, Liu TL, Huang N et al. Prescription of atropine eye drops among children diagnosed with myopia in Taiwan from 2000 to 2007: a nationwide study. Eye (Lond) 2013; 27(3): 418–424.
    1. Shih YF, Hsiao CK, Chen CJ, Chang CW, Hung PT, Lin LL. An intervention trial on efficacy of atropine and multi-focal glasses in controlling myopic progression. Acta Ophthalmol Scand 2001; 79(3): 233–236.
    1. Li SM, Wu SS, Kang MT, Liu Y, Jia SM, Li SY et al. Atropine slows myopia progression more in Asian than white children by meta-analysis. Optom Vis Sci 2014; 91(3): 342–350.
    1. Maaijwee KJ, Meulendijks CF, Radner W, van Meurs JC, Hoyng CB. [The Dutch version of the Radner Reading Chart for assessing vision function]. Ned Tijdschr Geneeskd 2007; 151(45): 2494–2497.
    1. Lin L, Lan W, Liao Y, Zhao F, Chen C, Yang Z. Treatment outcomes of myopic anisometropia with 1% atropine: a pilot study. Optom Vis Sci 2013; 90(12): 1486–1492.
    1. Tong L, Huang XL, Koh AL, Zhang X, Tan DT, Chua WH. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine. Ophthalmology 2009; 116(3): 572–579.
    1. Chia A, Chua WH, Wen L, Fong A, Goon YY, Tan D. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol 2014; 157(2): 451–457 e1.
    1. Lawwill T, Crockett S, Currier G. Retinal damage secondary to chronic light exposure, thresholds and mechanisms. Doc Ophthalmol 1977; 44(2):379–402.
    1. Noell WK, Walker VS, Kang BS, Berman S. Retinal damage by light in rats. Invest Ophthalmol 1966; 5(5): 450–473.
    1. Wu J, Seregard S, Algvere PV. Photochemical damage of the retina. Surv Ophthalmol 2006; 51(5): 461–481.
    1. Luu CD, Lau AM, Koh AH, Tan D. Multifocal electroretinogram in children on atropine treatment for myopia. Br J Ophthalmol 2005; 89(2): 151–153.
    1. Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2). Ophthalmology 2012; 119(2): 347–354.
    1. Kennedy RH, Dyer JA, Kennedy MA, Parulkar S, Kurland LT, Herman DC et al. Reducing the progression of myopia with atropine: a long term cohort study of Olmsted County students. Binocul Vis Strabismus Q 2000; 15(3 Suppl): 281–304.
    1. Rosenbaum AL, Bateman JB, Bremer DL, Liu PY. Cycloplegic refraction in esotropic children. Cyclopentolate versus atropine. Ophthalmology 1981; 88(10): 1031–1034.
    1. Nickla DL, Zhu X, Wallman J. Effects of muscarinic agents on chick choroids in intact eyes and eyecups: evidence for a muscarinic mechanism in choroidal thinning. Ophthalmic Physiol Opt 2013; 33(3): 245–256.
    1. McBrien NA, Stell WK, Carr B. How does atropine exert its anti-myopia effects? Ophthalmic Physiol Opt 2013; 33(3): 373–378.
    1. Arumugam B, McBrien NA. Muscarinic antagonist control of myopia: evidence for M4 and M1 receptor-based pathways in the inhibition of experimentally-induced axial myopia in the tree shrew. Invest Ophthalmol Vis Sci 2012; 53(9): 5827–5837.
    1. McBrien NA, Moghaddam HO, Reeder AP. Atropine reduces experimental myopia and eye enlargement via a nonaccommodative mechanism. Invest Ophthalmol Vis Sci 1993; 34(1): 205–215.
    1. Barathi VA, Chaurasia SS, Poidinger M, Koh SK, Tian D, Ho C et al. Involvement of GABA transporters in atropine-treated myopic retina as revealed by iTRAQ quantitative proteomics. J Proteome Res 2014; 13(11): 4647–4658.
    1. Gallego P, Martinez-Garcia C, Perez-Merino P, Ibares-Frias L, Mayo-Iscar A, Merayo-Lloves J. Scleral changes induced by atropine in chicks as an experimental model of myopia. Ophthalmic Physiol Opt 2012; 32(6): 478–484.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir